RecruitingPhase 2NCT07254000
Anakinra Pilot 2 - A Study to Optimise Dose and Route of Administration of Anakinra in Preterm Infants
Sponsor
Monash Medical Centre
Enrollment
24 participants
Start Date
Jun 27, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
A phase 2 randomised, three-arm, parallel-group, dose-ranging trial to determine safety, efficacy and optimal dosing of intravenous anakinra in premature neonates, with subcutaneous pharmacokinetic sub-study.
Eligibility
Min Age: 24 WeeksMax Age: 29 Weeks
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Anakinra (Kineret®) for people with inflammation, premature infants, and other related conditions. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 24 Weeks to 29 Weeks.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGAnakinra (Kineret®)
Standard care plus Anakinra for 21 days
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07254000
Related Trials
Innovative Steroid Treatment to Reduce Asthma Development in Children After First-time Rhinovirus Induced Wheezing
NCT038897438 locations
Natural History of the Human Biological Response to Environmental Exposure and Injury
NCT048889231 location
Independent and Combined Effects of Short-term Sulforaphane Supplementation and Exercise on Immunometabolism in Healthy Adults
NCT076685961 location
Short-Chain Fatty Acids in Lypopolysaccharide-Induced Inflammation and Executive Function
NCT077136411 location
Pumpkin Seed Oil as a Nutraceutical for Hemodialysis Patients
NCT077101831 location